These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 6428619)

  • 1. The difficult choice of treatment for poorly controlled maturity onset diabetes: tablets or insulin?
    Peacock I; Tattersall RB
    Br Med J (Clin Res Ed); 1984 Jun; 288(6435):1956-9. PubMed ID: 6428619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus.
    Groop L; Widén E; Franssila-Kallunki A; Ekstrand A; Saloranta C; Schalin C; Eriksson J
    Diabetologia; 1989 Aug; 32(8):599-605. PubMed ID: 2506091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum C-peptide after 6 months on glibenclamide remains higher than during insulin treatment.
    Peacock I; Watts R; Selby C; Tattersall RB
    Diabetes Res; 1987 Oct; 6(2):57-9. PubMed ID: 3123115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles.
    Hermann LS; Karlsson JE; Sjöstrand A
    Eur J Clin Pharmacol; 1991; 41(3):263-5. PubMed ID: 1748145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of insulin and glibenclamide in the treatment of elderly non-insulin dependent (type 2) diabetic patients.
    Kyllästinen M; Groop L
    Ann Clin Res; 1985; 17(3):100-4. PubMed ID: 3931537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Teraphy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial Glycemia.
    Buturovic BA; Ristic LB; Narancic AM
    Med Arch; 2014 Oct; 68(5):313-6. PubMed ID: 25568561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin, glibenclamide or metformin treatment for non insulin dependent diabetes: heterogenous responses of standard measures of insulin action and insulin secretion before and after differing hypoglycaemic therapy.
    Boyd K; Rogers C; Boreham C; Andrews WJ; Hadden DR
    Diabetes Res; 1992 Feb; 19(2):69-76. PubMed ID: 1286541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability profile of metformin/glibenclamide combination tablets (Glucovance): a new treatment for the management of type 2 diabetes mellitus.
    Davidson JA; Scheen AJ; Howlett HC
    Drug Saf; 2004; 27(15):1205-16. PubMed ID: 15588116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effects of addition of oral spray insulin (Oralin) on insulin secretion and metabolic control in subjects with type 2 diabetes mellitus suboptimally controlled on oral hypoglycemic agents.
    Guevara-Aguirre J; Guevara M; Saavedra J; Mihic M; Modi P
    Diabetes Technol Ther; 2004 Feb; 6(1):1-8. PubMed ID: 15000763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response of regimens of insulin therapy in type 2 diabetes mellitus subjects with secondary failure.
    Zargar AH; Masoodi SR; Laway BA; Wani AI; Bashir MI
    J Assoc Physicians India; 2002 May; 50(5):641-6. PubMed ID: 12186116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of oral hypoglycaemic drugs on serum lipids and lipoproteins in non-insulin-dependent diabetes (NIDDM).
    Elkeles RS
    Diabete Metab; 1991 May; 17(1 Pt 2):197-200. PubMed ID: 1936476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of oral antidiabetic agents on plasma amylin level in patients with non-insulin-dependent diabetes mellitus (type 2).
    Zapecka-Dubno B; Czyzyk A; Dworak A; Bak MI
    Arzneimittelforschung; 1999 Apr; 49(4):330-4. PubMed ID: 10337452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy of metformin and glibenclamide in patients with non-insulin-dependent diabetes mellitus.
    Hermann LS; Bitzén PO; Kjellström T; Lindgärde F; Scherstén B
    Diabete Metab; 1991 May; 17(1 Pt 2):201-8. PubMed ID: 1936477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).
    Mathieu C; Rodbard HW; Cariou B; Handelsman Y; Philis-Tsimikas A; Ocampo Francisco AM; Rana A; Zinman B;
    Diabetes Obes Metab; 2014 Jul; 16(7):636-44. PubMed ID: 24443830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin.
    Maffioli P; Fogari E; D'Angelo A; Perrone T; Derosa G
    Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1113-22. PubMed ID: 23524525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adding glimepiride to insulin+metformin in type 2 diabetes of more than 10 years' duration--a randomised, double-blind, placebo-controlled, cross-over study.
    Nybäck-Nakell Å; Adamson U; Lins PE; Landstedt-Hallin L
    Diabetes Res Clin Pract; 2014 Feb; 103(2):286-91. PubMed ID: 24485398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of bedtime NPH insulin or metformin combined with glibenclamide in secondary sulphonylurea failure in obese type II (NIDDM) patients.
    Niazi R; Muzaffar Z
    J Pak Med Assoc; 1998 Nov; 48(11):336-8. PubMed ID: 10323055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term effects of continuous subcutaneous insulin infusion treatment on insulin secretion in non-insulin-dependent overweight patients with poor glycaemic control despite maximal oral anti-diabetic treatment.
    Valensi P; Moura I; Le Magoarou M; Pariès J; Perret G; Attali JR
    Diabetes Metab; 1997 Feb; 23(1):51-7. PubMed ID: 9059766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.